Simon Harrison, MBBS, PhD, shares results from a phase I first-in-human trial evaluating AMG 701, an anti‑BCMA BiTE® molecule, in patients with heavily pre‑treated relapsed/refractory multiple myeloma.
Recent Articles
Editor’s Corner: All Those YESterdays
A few weeks ago, I was on a Zoom call with a candidate interviewing for a faculty position. The topic of work-life balance came...
New Children’s Hospital Coalition Aims to Combat Pandemic-Driven Drug Shortages
Eleven children’s hospitals have teamed up to form The Children’s Hospital Coalition, aimed at mitigating the effects of drug shortages caused by the COVID-19...
Study Finds Children with Down Syndrome Have Higher Risk of AML
Children with Down syndrome have an estimated 150-fold higher risk of developing acute myeloid leukemia (AML) before age five, compared to children without Down...
Biden Administration Proposes $6.5 Billion Health Research Agency
The U.S. federal government has proposed dedicating $6.5 billion to establish a medical research agency focused on curing cancer, Alzheimer’s, diabetes, and other diseases.
If...
European Commission Approves Selinexor Plus Dexamethasone for Relapsed/Refractory Myeloma
Selinexor, in combination with dexamethasone, has been granted conditional marketing authorization by the European Commission (EC) for the treatment of adult patients with multiple...
Current Issue
April 2021 Volume 7 Issue 5
This issue examines long-haul COVID-19, central nervous system relapse in non-Hodgkin lymphoma, and more.